Resistance to two heterologous neurotropic oncolytic viruses, Semliki Forest virus and vaccinia virus, in experimental glioma

J Virol. 2013 Feb;87(4):2363-6. doi: 10.1128/JVI.01609-12. Epub 2012 Dec 5.

Abstract

Attenuated Semliki Forest virus (SFV) may be suitable for targeting malignant glioma due to its natural neurotropism, but its replication in brain tumor cells may be restricted by innate antiviral defenses. We attempted to facilitate SFV replication in glioma cells by combining it with vaccinia virus, which is capable of antagonizing such defenses. Surprisingly, we found parenchymal mouse brain tumors to be refractory to both viruses. Also, vaccinia virus appears to be sensitive to SFV-induced antiviral interference.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Disease Models, Animal
  • Glioma / therapy*
  • Mice
  • Oncolytic Viruses / growth & development*
  • Oncolytic Viruses / immunology*
  • Semliki forest virus / growth & development*
  • Semliki forest virus / immunology*
  • Vaccinia virus / growth & development*
  • Vaccinia virus / immunology*